Esperion Therapeutics | ESPR - Sales Revenues


Esperion Therapeutics reported $51.63M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Alterity Therapeutics Limited AUD 11.38K 10.23K Dec/2022
Amarin USD 49.67M 23.07M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Cipla INR 75.18B 710M Dec/2025
CSL USD 3.54B 4.68B Jun/2025
Cytokinetics USD 1.93M 64.83M Sep/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Geron USD 47.2M 1.8M Sep/2025
Grifols EUR 2.18B 37.55M Sep/2025
Halozyme Therapeutics USD 354M 148M Sep/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.02B 878M Sep/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
United Therapeutics USD 799.5M 900K Sep/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024